Exelixis Inc (EXEL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché EXEL Giù? Forum Previsione

Perché le azioni Exelixis Inc (EXEL) sono in ribasso?

Abbiamo notato un calo di 5.16% nelle azioni di Exelixis Inc (EXEL) durante la sessione di negoziazione di 2025-12-08. Sebbene ciò possa essere attribuito alla normale volatilità o a vari fattori interni ed esterni, tieni presente che stiamo monitorando attivamente la situazione e forniremo aggiornamenti tempestivi il prima possibile!

2023-10-23:

Shares of Exelixis, Inc. (EXEL) dropped by 8.81% from $21.11 to $19.25 in the trading on Monday, October 23, 2023. The reason why EXEL stock down is due to the company's announcement on detailed results from its Phase 3 CABINET pivotal evaluating Cabozantinib in advanced neuroendocrine tumors:

The CABINET trial achieved its primary objective, showing significant improvements in median progression-free survival (PFS) for patients with advanced pancreatic neuroendocrine tumors (pNET) and extra-pancreatic NET (epNET).
The trial was halted early due to the remarkable efficacy observed during an interim analysis, with consistent safety profiles.
Exelixis plans to discuss these findings with the FDA to potentially offer a new treatment option for patients with these challenging cancers. Investors' cautious response to this news led to the decline in Exelixis, Inc.'s stock price.

RPRX

$40.65

2.52%

GMAB

$33.10

4.09%

INCY

$106.66

4.78%

BNTX

$98.09

1.28%

ONC

$320.35

0.02%

INSM

$175.07

0.07%

Exelixis Inc (EXEL)

Perché le azioni Exelixis Inc (EXEL) sono in ribasso?

Simile a EXEL